explore -WSS

explore

author：explore 2025-10-01 00:59:25 - browse：2932

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Deposition: Sackler embraced plan to conceal OxyContin’s strength

knowledge

WSS

Curing rare childhood diseases will falter unless Congress steps up

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readers discuss the intersection of pregnancy and addiction

Sen. Paul opposes bill to ban Chinese biotechs

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

The drug industry has found itself all alone in Washington

hotspot

explore

hotspot

Affirmative action in medical school literally saved lives

Amylyx ALS drug failure raises questions and concerns

Cancer drug shortages should be causing more outrage

Moderna says combo Covid

Hollywood unions extend contract negotiations for actors

Statins may not be needed by millions of people, study suggests

Drug repurposing or repositioning? The language matters

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

entertainment

First medicine developed to treat MASH expected to be approved soon

Study: Why relieving medical debt did not improve financial outcomes

Teladoc has a new CEO, but challenges remain the same

Stephen Quake on the Chan Zuckerberg quest to conquer disease

The problem with charging patients to message their doctors

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

hotspot

explore

knowledge

Wikipedia